NEW YORK, NY (20 January 2022) — Today, TB Alliance announced that it has received funding from the United States Agency for […]
(BERLIN/GENEVA, 13 January 2022) – The German Federal Ministry of Education and Research (BMBF) through KfW has granted additional funding to
TaBriX is a new spin-out company from The University of Manchester (UoM) with the mission to create novel anti-virulence drugs
TBAJ-587-CL-001 is the first Phase 1 trial in humans conducted by TB Alliance through the European Regimen Accelerator for Tuberculosis
New results from operational research in Ukraine and MSF’s TB-PRACTECAL study on drug-resistant forms of tuberculosis to be presented PRETORIA
“We have seen a number of highly promising breakthroughs in tuberculosis (TB) drug development over the past few years, but
NEW YORK (Sept 30, 2021)—TB Alliance, a not-for-profit organization dedicated to development and delivery of improved regimens to fight tuberculosis
Agreement between non-profit product development partnership and multinational pharmaceutical company will expand access to new TB drug NEW YORK and
TB Alliance’s Community Engagement (CE) forums provide an opportunity for capacity building and for members of TB-affected communities to share
NEW YORK (July 15, 2021)—To advance anti-tuberculosis (TB) science and enable the progression of new, safe, and affordable treatment solutions
